Making antibody treatments more effective in early Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether a special 3Tesla MRI scan can improve how well antibody treatments work for people with early Alzheimer's disease. The goal is to see if the scan helps make the treatment more effective and safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 90 years old.
- You have early Alzheimer's disease (mild cognitive impairment or mild dementia) confirmed by a spinal tap or PET scan.
- You and your doctor plan to start a standard antibody treatment (like lecanemab or donanemab).
- You have not had a stroke, more than 4 tiny brain bleeds, or other brain conditions that could interfere.
- You are not on blood thinners and do not have a bleeding disorder.
- You can have MRI and PET scans safely (no metal implants or severe claustrophobia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a monoclonal antibody therapy—a lab-made protein—to see if it can slow Alzheimer's symptoms. You may qualify if you have early Alzheimer's or mild cognitive impairment with a positive PET scan, and you can't have other major health issues like uncontrolled diabetes or heart problems.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This study tests antibody treatments that target amyloid plaques in the brain for people with mild memory or thinking problems. It may help determine if you are a candidate for these new drugs and monitors your safety through regular scans and checkups.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
This study tests an investigational drug, ARO-MAPT-SC, which targets a protein involved in Alzheimer's disease. It is for people with early Alzheimer's to see if the drug is safe and can slow the disease.
Hear when a new Alzheimer Dementia (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.